Lv5
1274 积分 2023-05-10 加入
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
17天前
已完结
Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia
20天前
已完结
Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia
20天前
已完结
Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review
22天前
已完结
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL
1个月前
已关闭
Venetoclax Plus Pediatric Regimen in Adolescents and Adults with Ph-Negative Acute Lymphoblastic Leukemia
1个月前
已完结
Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study
3个月前
已完结
Venetoclax Plus Pediatric Regimen in Adolescents and Adults with Ph-Negative Acute Lymphoblastic Leukemia
3个月前
已关闭
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma
3个月前
已完结
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma
3个月前
已完结
皖公网安备34019202002308
